novo glp 1 drugs Blockbuster GLP-1 Diabetes and Weight Loss Fails in Alzheimer's Trial Scoring 2 Million Prescriptions, Novo's

Obesity causes organ dysfunction via several pathophysiological mechanisms, ranging from the physical impact of increased adipose tissue mass, the presence of ectopic fat within tissues and organs, metabolic effects, inflammatory mechanisms, and psychological consequences [4,5]

Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial

95% CI 0.91 to 3.76

1):S52-S59

Increasing GLP-1 in the postprandial period correlates with the increase in blood flow in brain areas related to satiety, such as the hypothalamus and areas of the prefrontal cortex [53]

Endocrine Related Cancer , 19 (5), F77